Sonja Van Den Oudenrijn

Title: Sonja Van Den Oudenrijn: Innovator in Myeloid Cell Malignancies

Introduction

Sonja Van Den Oudenrijn is a prominent inventor based in Uithoorn, Netherlands. She has made significant contributions to the field of medical research, particularly in the treatment of myeloid cell malignancies. With a total of three patents to her name, her work focuses on innovative solutions for complex health issues.

Latest Patents

Her latest patents include groundbreaking developments related to binding molecules for the treatment of myeloid cell malignancies. These patents provide a human C-type lectin and binding molecules that specifically target this lectin. The inventions also encompass nucleic acid molecules encoding the binding molecules or the human C-type lectin, as well as compositions that include these binding molecules. The human C-type lectin is specifically expressed on myeloid cells, and the binding molecules capable of targeting it can be utilized in the diagnosis, prevention, and treatment of neoplastic disorders and diseases.

Career Highlights

Sonja is currently associated with Crucell Holland B.V., where she continues to advance her research and innovations. Her work has been instrumental in developing therapeutic strategies that address critical health challenges.

Collaborations

Some of her notable coworkers include Marja Van Meijer and Alexander Berthold Hendrik Bakker, who contribute to her research endeavors.

Conclusion

Sonja Van Den Oudenrijn's innovative work in the field of myeloid cell malignancies showcases her dedication to improving medical treatments. Her patents reflect her commitment to advancing healthcare solutions and her impact on the scientific community is significant.